Jiangsu Hansoh Pharmaceutical Co., Ltd.

This study is testing whether an experimental capsule called HS-10542 can help control IgA nephropathy, a kidney disease where protein leaks into urine. About 90 adults with confirmed IgA nephropathy will take either the drug or a placebo for 24 weeks to see if it safely reduces …

This study is testing an investigational injection called HS-20094 for adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Over 200 participants will be randomly assigned to receive either the real injection or a placebo (dummy shot) f…

This study is testing a new drug called HS-10566 for people with high-risk bladder cancer that hasn't spread into the muscle wall. It's for patients who are not eligible for or refuse surgery to remove their bladder. The research will first find a safe dose and then see how well …

This early-stage study is testing a new combination therapy called HS-10504 for people with advanced non-small cell lung cancer that has continued to grow despite previous treatments. The main goals are to find the safest and most effective dose and to see how well the body handl…

This study compares a new weekly injection called HS-20094 against an established diabetes medication (dulaglutide) in people with type 2 diabetes. About 546 participants whose blood sugar isn't well controlled on metformin, with or without another common pill, will receive one o…

This is a very early study to see if a new injection called HS-20136-2 is safe for people. It will be given once to about 38 healthy adults to check for side effects and see how the body handles it. The main goal is to gather basic safety information before testing it in people w…